Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients

BJU International

Volumn 111, Issue 3, 2013, Pages 396-403

  Iremashvili, Viacheslav ^a   Manoharan, Murugesan ^a   Lokeshwar, Soum D ^a   Rosenberg, Daniel L ^a   Pan, David ^a   Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

active surveillance; prostate biopsy; prostate cancer; prostate specific antigen; prostate specific antigen doubling time; prostate specific antigen velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DOUBLING TIME; PROSTATE SPECIFIC ANTIGEN VELOCITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84874667444     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11295.x     Document Type: Article

References (22)

1. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-2131
2. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
3. Singh PB, Ahmed HU, Emberton M,. Active surveillance: is there a need for better risk stratification at the outset? J Clin Oncol 2010; 28: e513; author reply e4
4. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J,. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007; 120: 170-174
5. Ng MK, Van As N, Thomas K, et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int 2009; 103: 872-876
6. Al Otaibi M, Ross P, Fahmy N, et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 2008; 113: 286-292
7. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-2816
8. Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011; 185: 1656-1660
9. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 2232-2241
10. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-1527
11. Network NCC. NCCN clinical practice guidelines in oncology: prostate cancer early detection. 2011. Available at: http://www.nccn.org/professionals/ physician-gls/pdf/prostate-detection.pdf. Accessed September 2011
12. Yu X, Loeb S, Roehl KA, Han M, Catalona WJ,. The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol 2007; 177: 1298-1302; discussion 301-2
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374
14. Vollmer RT, Humphrey PA,. Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. Am J Clin Pathol 2003; 119: 80-89
15. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML,. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174: 2191-2196
16. D'Amico AV, Renshaw AA, Sussman B, Chen MH,. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-447
17. Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ,. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol 2006; 176: 1399-1403
18. D'Amico AV, Chen MH, Roehl KA, Catalona WJ,. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-135
19. Vickers AJ, Savage C, O'Brien MF, Lilja H,. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403
20. King CR, Freedland SJ, Terris MK, et al. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 2007; 69: 732-737
21. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2011; 29: 2795-2800
22. Loeb S, Chan DW, Sokoll L, et al. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol 2008; 180: 1959-1962; discussion 62-3